设为首页 加入收藏

TOP

Telzir 50 mg/ml oral suspension Amprenavir
2014-08-30 23:32:37 来源: 作者: 【 】 浏览:302次 评论:0

For doctors

 

What is it and how is it used?

Telzir is used to treat HIV (human immunodeficiency virus) infection.

Telzir is a type of medicine known as an anti-retroviral. It is taken with low doses of another medicine, ritonavir, which boosts the level of Telzir in the blood. Telzir belongs to a group of anti-retroviral medicines called protease inhibitors. Protease is an enzyme produced by HIV which enables the virus to multiply in white blood cells (CD4 cells) in your blood. By stopping protease from working, Telzir stops HIV multiplying and infecting more CD4 cells

Telzir with low doses of ritonavir is used in combination with other anti-retroviral medicines (‘combination therapy’) to treat adults, adolescents and children aged over 6 years infected with HIV.

HIV can become resistant to anti-HIV medicines. To avoid this happening, and to stop your illness getting worse, it is very important that you keep taking all your medicines exactly as prescribed.

Telzir will not stop you passing on HIV. HIV infection is spread by sexual contact with someone who’s got the infection, or by transfer of infected blood (for example by sharing needles).

What do you have to consider before using it?

Telzir is to be taken in combination with low doses of ritonavir and other antiretroviral medicines. It is therefore important that you carefully read the package leaflet provided with these medicines. If you have any further questions about ritonavir or the other medicines prescribed, please ask your doctor or pharmacist.

Don’t take Telzir:

Tell your doctor if any of these applies to you.

Take special care with Telzir
Before you take Telzir
your doctor needs to know :

Tell your doctor if any of these applies to you. You will need extra check-ups, including blood tests, while you’re taking your medication.

Your doctor will monitor your blood glucose levels before and during treatment with Telzir.

Look out for important symptoms
Some people taking medicines for HIV infection develop other conditions, which can be serious. These include:

You may get a skin rash.
However you can still continue to take Telzir.It can be treated with antihistamines. Rarely, the skin rash can be severe and serious ( Stevens Johnson syndrome). If this happens, Telzir must be stopped immediately and you must never take it again.

Protect other people
Telzir will not stop you passing HIV infection on to other people, by having sex or by blood transfer. To protect other people from becoming infected with HIV:
Use a condom when you have oral or penetrative sex.
Don’t risk blood transfer – for example, don’t share needles.

Other medicines and Telzir
Tell your doctor or pharmacist if you’re taking any other medicines, if you’ve taken any recently, or if you start taking new ones
– these include herbal medicines or other medicines you bought without a prescription.
Your doctor will decide if these medicines are suitable for you to take with Telzir and ritonavir. This is very important, as Telzir or ritonavir can strengthen or weaken the effects of other medicines. This can sometimes lead to serious medical conditions.

There are some medicines that must not be taken with Telzir. You must check the list of medicines under 'Don't take Telzir' at the beginning of section 2 of this leaflet.

These medicines are not recommended with Telzir/ritonavir:

You will be closely monitored if you are taking these medicines with Telzir/ritonavir:

Your dose of Telzir may need to be changed if you are taking

Hormonal contraception
Taking Telzir and ritonavir while taking the contraceptive pill may harm your liver and may stop the contraceptive from working properly.
Use an alternative non-hormonal type of contraception such as a condom.
No studies have been done on the use of Telzir/ritonavir with other hormonal therapies, such as hormone replacement therapy (HRT).

Taking Telzir and food
Adults
should take the Telzir oral suspension without food and on an empty stomach. Children and adolescents should take the Telzir oral suspension with food.

Pregnancy and breast feeding
If you are pregnant, if you become pregnant, or if you are planning to become pregnant: → Talk to your doctor about the risks and benefits of taking Telzir.

Women who are HIV-positive must not breast feed because HIV infection can be passed on to the baby in breast milk. If you’re breast feeding, or thinking about breast feeding:
Talk to your doctor.

Important information about ingredients of Telzir oral suspension
Telzir oral suspension contains propyl and methyl parahydroxybenzoate. These ingredients may cause allergic reactions (sometimes delayed).

Driving and using machines
Telzir can make you feel dizzy and have other side effects that make you less alert. → Don’t drive or operate machinery unless you’re feeling well.

Stay in regular contact with your doctor
Telzir helps to control your condition, but it is not a cure for HIV infection. You need to keep taking it every day to stop your illness getting worse. You may still develop other infections and illnesses linked to HIV infection.
Keep in touch with your doctor, and don’t stop taking Telzir without your doctor’s advice.

How is it used?

Always take Telzir exactly as your doctor has told you. It is very important that you take the full daily dose of Telzir and ritonavir as prescribed by your doctor. Do not take more than the recommended dose. Check with your doctor or pharmacist if you are not sure.

Shake the bottle for 20 seconds before the first use. Shake the bottle for 5 seconds before subsequent uses.

A dosing syringe with a 10 ml graduation is supplied with the pack so you can measure your dose accurately.

How much to take

Adults Adults should take the Telzir oral suspension without food and on an empty stomach. The recommended dose is 14 ml Telzir oral suspension (700 mg fosamprenavir) twice daily with 100 mg ritonavir (as capsule or oral solution) twice daily.

Children from 6 years of age and weighing at least 25 kg
Children
should take the Telzir oral suspension with food.

Your doctor will work out the right dose based on your weight.

The recommended dose is 0.36 ml/kg of Telzir oral suspension (18 mg per kg fosamprenav ir) twice daily with 3 mg/kg ritonavir oral solution twice daily.

No dosing recommendations can be made for children weighing less than 25 kg.

Children can take the adult dose of ritonavir capsules (100 mg twice daily) if they weigh at least 33 kg and can swallow the capsules whole.

As an alternative to taking Telzir oral suspension:
Children can take the adult dose of one 700 mg Telzir tablet twice daily (with ritonavir 100 mg twice daily) if they weigh at least 39 kg and can swallow the tablets whole.

Children less than 6 years of age
Telzir is not recommended for children less than 6 years old.

Adults with liver disease
If you have mild liver disease, the dose is 14 ml Telzir oral suspension (700 mg fosamprenavir) twice daily with 100 mg ritonavir only once daily . If you have moderate liver disease the dose is 9 ml Telzir oral suspension (450 mg fosamprenavir) twice daily with 100 mg ritonavir only once daily. If you have severe liver disease the dose is 6 ml Telzir oral suspension (300 mgfosamprenavir) twice dailywith 100 mg ritonavir only once daily.

Step by step instructions
Do not mix Telzir with any other medicines in the bottle or the syringe.

1. Shake the bottle vigorously before use.

2. Remove the bottle cap and keep it safely.

3. Push the plastic adapter into the neck of the bottle, while holding the bottle firmly.

4. Insert the syringe firmly into the adapter.

5. Turn the bottle upside down.

6. Pull out the syringe plunger until the first portion of your full dose is withdrawn.

7. Turn the bottle the right way up and remove the syringe from the adapter.

8. Put the syringe into your mouth, placing the tip of the syringe against the inside of your cheek. Slowly push the plunger in, allowing time to swallow. Don’t push too hard and squirt the liquid into the back of the throat or you may choke.

9. Repeat steps to in the same way until you have taken the whole dose.

10. Do not leave the syringe in the bottle. Take the syringe and the adapter off and wash them thoroughly in clean water. Let them dry completely before you use them again.

11. Close the bottle tightly with the cap.

If you take too much Telzir
If you have taken more than the prescribed dose of Telzir:
Contact your doctor or pharmacist immediately for advice.

If you forget to take Telzir
If you forget to take a dose of Telzir, take it as soon as you remember and then continue your treatment as before. Don’t take a double dose to make up for a missed dose.

Don’t stop Telzir without advice
Take Telzir for as long as your doctor recommends. Don’t stop unless your doctor advises you to.

What are possible side effects?

Like all medicines, Telzir can cause side effects, but not everyone gets them. When treating HIV, it can be hard to tell whether side effects are caused by Telzir, by other medicines taken at the same time or by the HIV disease itself. For this reason, it is very important to talk to your doctor about any changes in your health.

Very common side effects
These may affect more than 1 in 10 people:

Common side effects
These may affect up to 1 in 10 people:

Uncommon side effects
These may affect up to 1 in 100 people:

Rare side effects
These may affect up to 1 in 1000 people:

You may experience muscle problems
There have been reports of muscle pain, tenderness or weakness, particularly with antiretroviral therapy including protease inhibitors and nucleoside analogues. On rare occasions, these muscle disorders have been serious ( rhabdomyolysis). If you notice any muscle problems:→ Tell your doctor.

Haemophiliacs may bleed more
In patients with haemophilia type A and B, there have been reports of increased bleeding while taking protease inhibitors. If this happens to you:
Talk to your doctor immediately.

If you get side effects
Tell your doctor or pharmacist if any of the side effects gets severe or troublesome, or if you notice any side effects not listed in this leaflet.

Other side effects of combination therapy for HIV

Old infections may flare up
People with advanced HIV infection (AIDS) have weak immune systems and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably caused by the body’s immune system becoming stronger, so that the body starts to fight these infections.

If you get any symptoms of infection or signs of inflammation while you’re taking Telzir:Tell your doctor immediately. Don’t take other medicines for the infection without your doctor’s advice.

Your body shape may change
People taking combination therapy may find that their body shape changes, because of changes in fat distribution:

It is not yet known what causes these changes, or whether they have any long-term effects on your health. If you notice changes in your body shape:
Tell your doctor.

You may have problems with your bones
Some people taking combination therapy for HIV develop a condition called osteonecrosis. With this condition, parts of the bone tissue die because of reduced blood supply to the bone.

People may be more likely to get this condition:

Other effects may show up in tests
Combination therapy for HIV can also cause:

How should it be stored?

Keep out of the reach and sight of children.

Do not freeze. Telzir does not require any other special storage conditions.

Do not use Telzir after the expiry date shown on the bottle and the carton.

Throw away the bottle 28 days after first opening it, but don’t dispose of medicine in your waste water or your household waste. Take it back to your pharmacist who will dispose of it in a way that won’t harm the environment.

↑ back to table of contents ↑

For doctors

What is it?

Telzir is a medicine that contains the active substance fosamprenavir. It is available as pink, capsule-shaped tablets (700 mg) and as an oral suspension (50 mg/ml).

What is it used for?

Telzir is used in combination with ritonavir and other antiviral medicines to treat patients aged six years or above who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). Doctors should prescribe Telzir to patients who have already taken medicines belonging to the same class as Telzir (protease inhibitors) only after they have looked at the antiviral medicines the patient has taken before and considered the likelihood that the virus will respond to the medicine.

The medicine can only be obtained with a prescription.

How is it used?

Treatment with Telzir should be started by a doctor who has experience in the management of HIV infection.

The recommended dose of Telzir for adults (aged 18 years or over) and for patients aged between six and 18 years who weigh more than 39 kg is 700 mg twice a day. In patients aged between six and 18 years who weigh between 25 and 39 kg, the dose depends on body weight. There is no recommended dose for patients below 18 years who weigh less than 25 kg.

Telzir tablets can be taken with or without food. The oral suspension should be taken without food on an empty stomach in adults, but in younger patients it should be taken with food in order to hide the taste and help them stick to treatment. In adults, each dose of Telzir must be given with 100 mg ritonavir, twice a day. In younger patients, the dose of ritonavir depends on body weight.

Adults with liver problems should take a reduced dose of Telzir and be closely monitored for safety and their response to treatment. For more information, see the package leaflet.

How does it work?

The active substance in Telzir, fosamprenavir, is a ‘prodrug’ of the protease inhibitor amprenavir, which means that it is converted into amprenavir in the body. Amprenavir has been authorised in the European Union (EU) since October 2000 as Agenerase. Amprenavir blocks an enzyme called protease, which is involved in the reproduction of HIV. When the enzyme is blocked, the virus does not reproduce normally, slowing down the spread of infection.

Ritonavir is another protease inhibitor that is used as a ‘booster’. It slows down the rate at which amprenavir is broken down, increasing the levels of amprenavir in the blood. This allows a lower dose of Telzir to be used for the same antiviral effect. Telzir, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level. Telzir does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.

How has it been studied?

Telzir has been studied in three main studies involving 1,862 adults infected with HIV. The first compared ritonavir-boosted Telzir with nelfinavir (another protease inhibitor) in treatment-naïve adults (who had previously taken treatment for HIV infection for no longer than four weeks). The other two studies compared Telzir with lopinavir (another protease inhibitor), both of which were boosted with ritonavir. In one of these studies, the patients were treatment-naïve, but in the other study, they had taken HIV treatment including protease inhibitors before. In all three studies, the patients also took two reverse transcriptase inhibitors (another type of antiviral medicine). The main measure of effectiveness was the level of HIV in the blood (viral load) in the first 48 weeks of treatment.

Telzir, taken in combination with other antiviral medicines, has also been assessed in one main study including 57 HIV-infected patients aged between two and 18 years.

What benefits has it shown during the studies?

In the studies of treatment-naïve adults, ritonavir-boosted Telzir was as effective as the comparator medicines, but it was less effective in adults who had been treated before. After 48 weeks, 69% of the treatment-naïve adults taking ritonavir-boosted Telzir (221 out of 322) and 68% of those taking nelfinavir (221 out of 327) had viral loads below 400 copies/ml. Similar results were seen in the study comparing Telzir with lopinavir, with around three-quarters of both groups of patients having viral loads below 400 copies/ml. In the study of patients who had been treated before, the patients taking lopinavir had larger reductions in viral loads over the first 48 weeks.

A similar benefit has also been seen in younger patients receiving Telzir. However, there were too few patients aged below six years to support the use of Telzir in this age group.

What is the risk associated?

The most common side effects in adults taking Telzir (seen in more than 1 patient in 10) are diarrhoea and increases in the levels of triglycerides (a type of fat) in the blood. Similar side effects are seen in younger patients. For the full list of all side effects reported with Telzir, see the package leaflet.

Telzir should not be used in people who may be hypersensitive (allergic) to fosamprenavir, amprenavir, any of the other ingredients, or ritonavir. Telzir must not be used in patients who are taking rifampicin (used to treat tuberculosis), St John’s wort (a herbal preparation used to treat depression), or medicines that are broken down in the same way as Telzir or ritonavir and are harmful at high levels in the blood. See the package leaflet for the full list of these medicines. As Telzir is converted into amprenavir in the body, it must not be given at the same time as other medicines containing amprenavir.

As with other anti-HIV medicines, patients taking Telzir may be at risk of lipodystrophy (changes in the distribution of body fat), osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system). Patients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Telzir.

Why has it been approved?

The CHMP concluded that Telzir, which contains a prodrug of amprenavir, provides an advantage for patients, as the number of tablets they need to take is reduced when compared to the number of Agenerase capsules that they would need to take for the same dose of amprenavir. Although the Committee noted that the use of ritonavir-boosted Telzir had not been studied sufficiently in heavily pretreated patients and that no comparative studies had been carried out in children, it decided that Telzir’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Further information

The European Commission granted a marketing authorisation valid throughout the EU for Telzir on 12 July 2004. The marketing authorisation holder is ViiV Healthcare UK Limited. The marketing authorisation is valid for an unlimited period.

For more information about treatment with Telzir, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

This summary was last updated in 06-2010.

↑ back to table of contents ↑
 

Name

 

Telzir 50 mg/ml oral suspension

 

Composition

 

Each ml of oral suspension contains 50 mg fosamprenavir as fosamprenavir calcium (equivalent to approximately 43 mg amprenavir).

Excipients:
Methyl parahydroxybenzoate (E218) 1.5 mg/ml
Propyl parahydroxybenzoate (E216) 0.2 mg/ml

For a full list of excipients, see section 6.1.

 

Pharmaceutical Form

 

Oral suspension.

The suspension is white to off-white in colour.

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Telzir 700 mg film-coated table.. 下一篇Telzir (fosamprenavir)

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位